Australia's most trusted
source of pharma news
Posted 21 October 2025 AM
Pfizer has new ammunition for the PBAC after the release of a trio of Phase 3 trials over the weekend, although all the drugs are sponsored by partners in Australia.
Pfizer and Astellas announced the final overall survival results from the Phase 3 EMBARK study, which evaluated Xtandi as a monotherapy and in combination with androgen deprivation therapy (ADT) leuprorelin (called leuprolide in the study) to treat metastatic hormone-sensitive prostate cancer, which saw eight-year overall survival rise to 78.9 per cent for patients taking the combination compared to 69.5 per cent for leuprorelin alone.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.